Related Experiment Videos

Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis

Luc M Van Bortel1, Francesco Fici, Flavio Mascagni

  • 1Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium. luc.vanbortel@ugent.be

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|February 29, 2008
PubMed

Insights

Nebivolol, a selective beta-blocker, demonstrated superior or comparable antihypertensive efficacy and better tolerability than other drug classes. This meta-analysis suggests nebivolol may be a beneficial first-line treatment for hypertension.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Lowering blood pressure (BP) is crucial for reducing cardiovascular risk.
  • Recent evidence questions the first-line use of traditional beta-blockers.
  • Nebivolol, a third-generation beta-blocker, offers vasodilation via nitric oxide (NO) release.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of nebivolol compared to other antihypertensive drugs and placebo.
  • To assess nebivolol's role in hypertension management.

Main Methods:

  • Meta-analysis of 12 randomized controlled studies.
  • Nebivolol 5 mg once daily compared against other antihypertensives, placebo, or both.
  • Studies selected via MEDLINE search up to 2007.

Main Results:

  • Nebivolol showed higher response rates than ACE inhibitors and all antihypertensives combined.
  • Efficacy was similar to other beta-blockers, CCAs, and losartan.
  • Nebivolol had significantly lower adverse event rates than losartan, CCAs, other beta-blockers, and all antihypertensives combined.

Conclusions:

  • Nebivolol 5 mg exhibits enhanced antihypertensive effects, potentially due to NO-mediated vasodilation.
  • It achieved comparable or superior BP normalization rates with excellent tolerability.
  • Nebivolol may offer advantages as a first-line hypertension therapy.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...